25 August 2020
The international iReceptor Plus consortium has gathered data of almost 200 million sequences of T and B cell receptor repertoires from COVID-19 patients. It is now offering its technology tools and infrastructure to share and analyze this unprecedented data resource with the scientific community, drug companies and researchers.
The EU- and Canadian-funded project currently offers information from seven different COVID-19 research studies carried out in the United States, Germany, the United Kingdom and China, with multiple patients through the iReceptor Gateway. This data is critical to the search for anti-COVID-19 therapeutics and vaccines. iReceptor Plus intends to add additional data sets in the coming weeks.
iReceptor Plus is dedicated to sharing and analyzing antibody and T-cell receptor (AIRR-seq) data from the immune system to accelerate vaccine discovery against pathogens such as the novel coronavirus.
“The new data can lead to discovering biomarkers, which can provide tools for diagnosis and treatment to prevent infection from COVID-19,” said Gur Yaari, associate professor at Bar-Ilan University, iReceptor Plus Project coordinator. “The COVID-19 data sets provide the infrastructure and data for the benefit of researchers in academia and industry alike.”
PrintNovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
03 November 2024
The State Duma may oblige marketplaces to guarantee the quality of dietary supplements
16 December 2024
The Center for Microfluidic Technologies has opened in Moscow
16 December 2024
Industry M&A volume declined 8% this year compared to '23: PwC
13 December 2024
The Russian Ministry of Health has created a Code of Ethics for AI in healthcare
13 December 2024